Eidos Therapeutics (FRA:6MX) Beginning Cash Position : €148.42 Mil (As of Sep. 2020)

View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Beginning Cash Position?

Eidos Therapeutics's Beginning Cash Position for the quarter that ended in Sep. 2020 was €148.42 Mil.

Eidos Therapeutics's quarterly Beginning Cash Position increased from Mar. 2020 (€173.00 Mil) to Jun. 2020 (€174.51 Mil) but then declined from Jun. 2020 (€174.51 Mil) to Sep. 2020 (€148.42 Mil).

Eidos Therapeutics's annual Beginning Cash Position increased from Dec. 2017 (€1.65 Mil) to Dec. 2018 (€4.83 Mil) and increased from Dec. 2018 (€4.83 Mil) to Dec. 2019 (€141.43 Mil).

Eidos Therapeutics Beginning Cash Position Historical Data

The historical data trend for Eidos Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Beginning Cash Position Chart

Eidos Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Beginning Cash Position

0.02

1.65

4.83

141.43

Eidos Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Beginning Cash Position	Get a 7-Day Free Trial											119.31	149.24	173.00	174.51	148.42

Eidos Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Eidos Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Eidos Therapeutics (FRA:6MX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (FRA:6MX) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104

Website

https://www.eidostx.com

Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.

Eidos Therapeutics (FRA:6MX) Headlines

No Headlines